[
  {
    "prompt": "Generate Cypher to store medical relations from text: Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant. A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described. This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. L\nCypher:",
    "target": "MERGE (h:Chemical {name: 'lithium carbonate'}) MERGE (t:Disease {name: 'cyanosis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Lithium carbonate'}) MERGE (t:Disease {name: 'cyanosis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'lithium carbonate'}) MERGE (t:Disease {name: 'cardiac arrhythmia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Lithium carbonate'}) MERGE (t:Disease {name: 'cardiac arrhythmia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'lithium carbonate'}) MERGE (t:Disease {name: 'neurologic depression'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Lithium carbonate'}) MERGE (t:Disease {name: 'neurologic depression'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Phenobarbital-induced dyskinesia in a neurologically-impaired child. A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures. Known causes of movement disorders were eliminated after evaluation. On repeat challenge with phenobarbital, the dyskinesia recurred. Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.\nCypher:",
    "target": "MERGE (h:Chemical {name: 'Phenobarbital'}) MERGE (t:Disease {name: 'dyskinesia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'phenobarbital'}) MERGE (t:Disease {name: 'dyskinesia'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Acute changes of blood ammonia may predict short-term adverse effects of valproic acid. Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs. A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours. Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were simila\nCypher:",
    "target": "MERGE (h:Chemical {name: 'valproic acid'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Valproic acid'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'VPA'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'ammonia'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Ammonia'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'NH3'}) MERGE (t:Disease {name: 'drowsiness'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data. The effects of i.v.c. injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats. Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity. Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striat\nCypher:",
    "target": "MERGE (h:Chemical {name: 'haloperidol'}) MERGE (t:Disease {name: 'catalepsy'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'apomorphine'}) MERGE (t:Disease {name: 'hyperactivity'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Development of isoproterenol-induced cardiac hypertrophy. The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight). A time course was established for the change in tissue mass, RNA and DNA content, as well as hydroxyproline content. Heart weight increased 44% after 8 days of treatment with a half time of 3.4 days. Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a\nCypher:",
    "target": "MERGE (h:Chemical {name: 'isoproterenol'}) MERGE (t:Disease {name: 'cardiac hypertrophy'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'ISO'}) MERGE (t:Disease {name: 'cardiac hypertrophy'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'isoproterenol'}) MERGE (t:Disease {name: 'hyperplasia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'ISO'}) MERGE (t:Disease {name: 'hyperplasia'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole. The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined. Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks. In groups given 2% BHA, although marked hyperpla\nCypher:",
    "target": "MERGE (h:Chemical {name: 'butylated hydroxyanisole'}) MERGE (t:Disease {name: 'forestomach carcinogenesis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'butylated hydroxyanisole'}) MERGE (t:Disease {name: 'forestomach tumorigenesis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'butylated hydroxyanisole'}) MERGE (t:Disease {name: 'forestomach tumors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'BHA'}) MERGE (t:Disease {name: 'forestomach carcinogenesis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'BHA'}) MERGE (t:Disease {name: 'forestomach tumorigenesis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'BHA'}) MERGE (t:Disease {name: 'forestomach tumors'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Ketanserin pretreatment reverses alfentanil-induced muscle rigidity. Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil. Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity. Intraperitoneal ketanserin administration at doses of 0.6\nCypher:",
    "target": "MERGE (h:Chemical {name: 'alfentanil'}) MERGE (t:Disease {name: 'muscle rigidity'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'alfentanil'}) MERGE (t:Disease {name: 'rigidity'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium. We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1. Significant differences between the four groups were detected (P less than 0.001). Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1). Use of gl\nCypher:",
    "target": "MERGE (h:Chemical {name: 'edrophonium'}) MERGE (t:Disease {name: 'bradycardias'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat. Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s). We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon, using male Sprague-Dawley rats anesthetized with ketamine. Under proper control of respiration, body temp\nCypher:",
    "target": "MERGE (h:Chemical {name: 'fentanyl'}) MERGE (t:Disease {name: 'muscular rigidity'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia. We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia. This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss. Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sin\nCypher:",
    "target": "MERGE (h:Chemical {name: 'epsilon-aminocaproic acid'}) MERGE (t:Disease {name: 'sagittal sinus thrombosis'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Hemorrhagic cystitis complicating bone marrow transplantation. Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation. As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation. In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with me\nCypher:",
    "target": "MERGE (h:Chemical {name: 'cyclophosphamide'}) MERGE (t:Disease {name: 'Hemorrhagic'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'cyclophosphamide'}) MERGE (t:Disease {name: 'hemorrhagic'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'cyclophosphamide'}) MERGE (t:Disease {name: 'cystitis'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study. The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II. The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study. Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, w\nCypher:",
    "target": "MERGE (h:Chemical {name: 'flumazenil'}) MERGE (t:Disease {name: 'nausea'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Flumazenil'}) MERGE (t:Disease {name: 'nausea'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'flumazenil'}) MERGE (t:Disease {name: 'vomiting'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Flumazenil'}) MERGE (t:Disease {name: 'vomiting'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports. Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported. Special reference is made to their clinical presentation, which may be totally asymptomatic. Liver-function tests are of little diagnostic value, but valuable information may be obtained from both liver scanning and hepatic angiography. Histologic differences \nCypher:",
    "target": "MERGE (h:Chemical {name: 'oral contraceptives'}) MERGE (t:Disease {name: 'focal nodular hyperplasia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'oral contraceptives'}) MERGE (t:Disease {name: 'adenomas'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'oral contraceptives'}) MERGE (t:Disease {name: 'adenoma'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia. Arterial thromboembolism is a recognized complication of systemic heparin therapy. Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The cli\nCypher:",
    "target": "MERGE (h:Chemical {name: 'heparin'}) MERGE (t:Disease {name: 'arterial occlusion'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'heparin'}) MERGE (t:Disease {name: 'thrombocytopenia'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure. BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown. AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality. METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004. We compared age-specific mortality rates f\nCypher:",
    "target": "MERGE (h:Chemical {name: 'paracetamol'}) MERGE (t:Disease {name: 'acute liver failure'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Paracetamol'}) MERGE (t:Disease {name: 'acute liver failure'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population. BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In ad\nCypher:",
    "target": "MERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'psychosis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'psychotic disorders'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'psychosis'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'psychotic disorders'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice. BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion-induced seizures. This is important, since different controlled release formulations of bupropion release the active drug at different rates. METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence an\nCypher:",
    "target": "MERGE (h:Chemical {name: 'bupropion hydrochloride'}) MERGE (t:Disease {name: 'seizures'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion hydrochloride'}) MERGE (t:Disease {name: 'convulsive'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion hydrochloride'}) MERGE (t:Disease {name: 'convulsions'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion'}) MERGE (t:Disease {name: 'seizures'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion'}) MERGE (t:Disease {name: 'convulsive'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion'}) MERGE (t:Disease {name: 'convulsions'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion HCl'}) MERGE (t:Disease {name: 'seizures'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion HCl'}) MERGE (t:Disease {name: 'convulsive'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'bupropion HCl'}) MERGE (t:Disease {name: 'convulsions'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Bupropion HCl'}) MERGE (t:Disease {name: 'seizures'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Bupropion HCl'}) MERGE (t:Disease {name: 'convulsive'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Bupropion HCl'}) MERGE (t:Disease {name: 'convulsions'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats. Penicillin model is a widely used experimental model for epilepsy research. In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats. Male Wistar rats were anesthetized with i.p. urethane and connected to an electrocorticogram setup. After a short period of basal activity recording, ep\nCypher:",
    "target": "MERGE (h:Chemical {name: 'penicillin-G potassium'}) MERGE (t:Disease {name: 'epileptiform activity'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'penicillin-G potassium'}) MERGE (t:Disease {name: 'epilepsy'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'penicillin-G potassium'}) MERGE (t:Disease {name: 'epileptic'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'penicillin-G potassium'}) MERGE (t:Disease {name: 'epilepsies'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: High dose dexmedetomidine as the sole sedative for pediatric MRI. OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine. AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies. BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies. Over time, an eff\nCypher:",
    "target": "MERGE (h:Chemical {name: 'dexmedetomidine'}) MERGE (t:Disease {name: 'bradycardia'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Dexmedetomidine'}) MERGE (t:Disease {name: 'bradycardia'}) MERGE (h)-[:INDUCES]->(t)"
  },
  {
    "prompt": "Generate Cypher to store medical relations from text: Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness. Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers. Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice. This increase in aggressiveness was not secondary to METH-induced hyperactivity. Analysis of protein expressi\nCypher:",
    "target": "MERGE (h:Chemical {name: 'Methamphetamine'}) MERGE (t:Disease {name: 'aggressiveness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Methamphetamine'}) MERGE (t:Disease {name: 'Aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Methamphetamine'}) MERGE (t:Disease {name: 'psychiatric disorders'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'Methamphetamine'}) MERGE (t:Disease {name: 'aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'aggressiveness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'Aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'psychiatric disorders'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'methamphetamine'}) MERGE (t:Disease {name: 'aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'aggressiveness'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'Aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'psychiatric disorders'}) MERGE (h)-[:INDUCES]->(t)\nMERGE (h:Chemical {name: 'METH'}) MERGE (t:Disease {name: 'aggressive behaviors'}) MERGE (h)-[:INDUCES]->(t)"
  }
]